Skip to main content

Table 1 Effect of baicalein treatment on cancer gene expression in-vivo. Genes shown to be up-regulated or down-regulated in H-460 cells following baicalein treatment, by qPCR. RNA was extracted from xenograft tumour tissue treated with baicalein and corresponding control tissue (n = 2/group). cDNA was prepared from this RNA and gene expression profiling carried out using Taqman quantitative PCR arrays (Cancer Profiler Arrays, Superarray). 11 genes were found to be differentially regulated (greater than 2 fold increase/decrease) in the baicalein-treated tumours, relative to vehicle-treated controls

From: Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo

Altered gene Gene name Function Fold change
CDC25A Cell division cycle 25A Cell cycle arrest. Allows time for DNA repair. −2.79
CHEK2 Checkpoint kinase 2 Cell cycle check-point regulator and tumor suppressor −2.24
E2F1 E2F transcription factor 1 Cell cycle control. Mediator of P53 - dependant apoptosis. +2.27
TNFRSF25 (DR3) TNF receptor superfamily; member 25 Increases apoptosis. Anti-metastatic. +3.4
ERBB2 V-ERB-B2 avian erythroblastic leukemia viral oncogene homolog 2 Oncogene. Mutations associated with lung cancer. −2.16
ITGA1 Integrin alpha-1 Involved in cell-cell adhesion. −2.11
ITGB3 Integrin beta-3 Cell adhesion and cell surface mediated signalling. Involvedin platelet aggregation. +6.96
FGFR-2 Fibroblast Growth factor R2 Angiogenic receptor. Inhibition blocks small cell lung cancer growth in-vitro and in-vivo. −8.27
IFNB-1 Interferon B1 Anti-tumor effects. −2.07
MMP-9 Matrix metalloproteinase-9 Invasion of tumour cells through basement membrane. Implicated in lung metastasis of breast tumours. +2.08
PLAU Urinary plasminogen activator Converts plasminogen to plasmin. Stimulates cell migration. +2.04